9995 — RemeGen Co Income Statement
0.000.00%
Last trade - 00:00- HK$38.21bn
- HK$40.41bn
- CNY1.72bn
Annual income statement for RemeGen Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3.04 | 1,426 | 772 | 1,083 | 1,717 |
| Cost of Revenue | |||||
| Gross Profit | 0.737 | 1,358 | 500 | 826 | 1,370 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 707 | 1,124 | 1,767 | 2,584 | 3,173 |
| Operating Profit | -704 | 303 | -995 | -1,502 | -1,456 |
| Gain / Loss on Sale of Assets | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -698 | 276 | -999 | -1,511 | -1,468 |
| Net Income After Taxes | -698 | 276 | -999 | -1,511 | -1,468 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -698 | 276 | -999 | -1,511 | -1,468 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -698 | 276 | -999 | -1,511 | -1,468 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.28 | 0.513 | -1.88 | -2.8 | -2.73 |
| Dividends per Share |